United States Food and Drug Administration (USFDA) has successfully completed inspection at Alembic Pharmaceuticals’ Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation. The inspection was conducted from October 7, 2024 to October 08, 2024. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.